Cargando…

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma

BACKGROUND AND PURPOSE: PD-1 and PD-L1 are involved in anticancer immunosurveillance, and their expression may be predictive for therapeutic effectiveness of specific antibodies. Their influence on response to neoadjuvant radiochemotherapy (RCT) and prognosis in patients with oesophageal adenocarcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göbel, Holger H., Distel, Luitpold V.R., Aigner, Thomas, Büttner-Herold, Maike J., Grabenbauer, Gerhard G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991306/ https://www.ncbi.nlm.nih.gov/pubmed/35402739 http://dx.doi.org/10.1016/j.ctro.2022.04.001

Ejemplares similares

Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under “Real World“ Conditions?
por: Grabenbauer, Alexander, et al.
Publicado: (2023)

Radiochemotherapy fosters a favorable pattern of inflammatory cells in head and neck tumors
por: Distel, Luitpold, et al.
Publicado: (2012)

Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal Cancer
por: Schuster, Barbara, et al.
Publicado: (2021)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Feasibility of a 12-month-exercise intervention during and after radiation and chemotherapy in cancer patients: impact on quality of life, peak oxygen consumption, and body composition
por: Grabenbauer, Alexander, et al.
Publicado: (2016)

Cell-in-cell structures are more potent predictors of outcome than senescence or apoptosis in head and neck squamous cell carcinomas
por: Schenker, Hannah, et al.
Publicado: (2017)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

Distribution of immune cells in head and neck cancer: CD8(+ )T-cells and CD20(+ )B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma
por: Pretscher, Dominik, et al.
Publicado: (2009)

Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia
por: Ries, Jutta, et al.
Publicado: (2021)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
por: Weber, Manuel, et al.
Publicado: (2019)

CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis
por: Olmes, Gregor, et al.
Publicado: (2016)

Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells
por: Łubgan, Dorota, et al.
Publicado: (2008)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Increase in non-professional phagocytosis during the progression of cell cycle
por: Hofmann, Alexander, et al.
Publicado: (2021)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: Powell, A. G. M. T., et al.
Publicado: (2020)

Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation
por: Gottwald, Dorian, et al.
Publicado: (2020)

CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer
por: Echarti, Alessia, et al.
Publicado: (2019)

The Prognostic and Predictive Significance of Tumor-Infiltrating Memory T Cells Is Reversed in High-Risk HNSCC
por: Hartan, Rebekka, et al.
Publicado: (2022)

Cell-in-cell phenomenon: leukocyte engulfment by non-tumorigenic cells and cancer cell lines
por: Bauer, Mareike F., et al.
Publicado: (2021)

Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia
por: Haas, Matthias, et al.
Publicado: (2009)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density
por: Schnellhardt, Sören, et al.
Publicado: (2022)

Non-Professional Phagocytosis Increases in Melanoma Cells and Tissues with Increasing E-Cadherin Expression
por: Unseld, Luzie Helene, et al.
Publicado: (2023)

Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
por: Jiang, William, et al.
Publicado: (2022)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma
por: Weber, Manuel, et al.
Publicado: (2017)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
por: Li, Zhiyang, et al.
Publicado: (2021)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Anastomotic Breakdown Five Years After Neoadjuvant Radiochemotherapy and Ultralow Anterior Resection for Rectal Adenocarcinoma
por: Nguyen, Eric, et al.
Publicado: (2020)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
por: Yang, Zhengyang, et al.
Publicado: (2022)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
por: Yuan, Zhen, et al.
Publicado: (2023)

Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI
por: Bostel, T., et al.
Publicado: (2020)

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer
por: Mallet, Romain, et al.
Publicado: (2020)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hgbsni520iphtsr843gi4lh3j7